STOCK TITAN

Xeris Biopharma Holdings Inc - XERS STOCK NEWS

Welcome to our dedicated news page for Xeris Biopharma Holdings (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xeris Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xeris Biopharma Holdings's position in the market.

Rhea-AI Summary
Xeris Biopharma Holdings, Inc. announces exchange agreements for convertible notes, providing financial flexibility and extending maturity date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
earnings
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) to Host Q2 2023 Financial Results Conference Call and Webcast at 8:30am ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences earnings
-
News
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced that it has shipped over one million units of Gvoke®, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes. This milestone comes in light of updated guidelines recognizing the importance of ready-to-use glucagon for people with diabetes at risk of severe hypoglycemia. The American Diabetes Association and others estimate that approximately 15 million people with diabetes are at increased risk of low blood sugar, emphasizing the need for products like Gvoke HypoPen®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.75%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences earnings
Xeris Biopharma Holdings Inc

Nasdaq:XERS

XERS Rankings

XERS Stock Data

286.52M
134.21M
3.87%
44.82%
6.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Chicago

About XERS

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.